The lesions seen in the degenerating neurons of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin positive inclusions (FTLD-U) consist primarily of the TDP-43 protein. How aggregated TDP-43 protein causes neuronal dysfunction and neurodegeneration is poorly understood. However, mutations in the gene encoding TDP-43 cause some forms of familial ALS proving that abnormal TDP-43 causes neurodegeneration. Furthermore, TDP-43 positive pathological lesions appear in postmortem samples from several different neurodegenerative disorders including FTLD-U, ALS, Alzheimer's disease (AD), Parkinson's disease, dementia with Lewy bodies, and Guam amyotrophic lateral sclerosis/Parkinson's dementia. To model TDP-43 neurotoxicity in a simple animal model, we have transgenically expressed human TDP-43 protein in the neurons of the nematode worm, C. elegans. Expression of human TDP-43 in worm neurons causes neuronal dysfunction and accumulation of nuclear inclusions consisting of aggregated insoluble TDP-43 protein. We have previously reported a C. elegans model for the tau pathology seen in human tauopathy disorders including and AD. We propose to use the same methodologies to characterize the new model for TDP-43 proteinopathy with a focus on the mechanisms of TDP-43 mediated neurotoxicity and how the localization of TDP-43 protein alters its toxicity. The neuronal consequences of tau and TDP-43 protein expression will be investigated by profiling the transcriptional and post-translational responses to neurotoxicity. Transcriptional changes will be monitored using an mRNA tagging/microarray hybridization approach to identify genes up-regulated and down-regulated in response to neurotoxicity. The, genetic pathways that normally act to protect against the neurotoxic effects of TDP-43 will be identified using a genome-wide RNAi screening approach. Genes normally required for tau neurotoxicity will also be tested for their ability to modify the neurotoxicity of TDP-43. The long term goal of this work is to develop neuroprotective strategies for neurodegenerative disorders with TPD-43 and tau protein deposits.
Deposits of abnormally folded aggregated protein are found in a number of disorders affecting the nervous system including Alzheimer's disease and amyotrophic lateral sclerosis. We have generated different animal models for the nerve cell death seen in these disorders using the worm, C. elegans to understand how protein misfolding can causes disease. Our current work focuses on the newly identified aggregating protein TDP-43, a protein that forms misfolded protein deposits in many different nervous system disorders.
|Guerrero, Erika N; Wang, Haibo; Mitra, Joy et al. (2016) TDP-43/FUS in motor neuron disease: Complexity and challenges. Prog Neurobiol 145-146:78-97|
|Liachko, Nicole F; Saxton, Aleen D; McMillan, Pamela J et al. (2016) The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. Acta Neuropathol 132:545-61|
|Salado, Irene G; Redondo, Miriam; Bello, Murilo L et al. (2014) Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem 57:2755-72|
|Dohi, Kenji; Kraemer, Brian C; Erickson, Michelle A et al. (2014) Molecular hydrogen in drinking water protects against neurodegenerative changes induced by traumatic brain injury. PLoS One 9:e108034|
|Liachko, Nicole F; McMillan, Pamela J; Strovas, Timothy J et al. (2014) The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genet 10:e1004803|
|Boyd, Justin D; Lee-Armandt, J Peter; Feiler, Marisa S et al. (2014) A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J Biomol Screen 19:44-56|
|McCormick, Allyson V; Wheeler, Jeanna M; Guthrie, Chris R et al. (2013) Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. Biol Psychiatry 73:464-71|
|Liachko, Nicole F; McMillan, Pamela J; Guthrie, Chris R et al. (2013) CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol 74:39-52|
|Korvatska, Olena; Strand, Nicholas S; Berndt, Jason D et al. (2013) Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Hum Mol Genet 22:3259-68|
|Watkins, Guy R; Wang, Ning; Mazalouskas, Matthew D et al. (2012) Monoubiquitination promotes calpain cleavage of the protein phosphatase 2A (PP2A) regulatory subunit Î±4, altering PP2A stability and microtubule-associated protein phosphorylation. J Biol Chem 287:24207-15|
Showing the most recent 10 out of 19 publications